Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
about
Vaccines for preventing herpes zoster in older adultsVaccination of healthcare workers: A reviewHerpes zoster vaccine (Zostavax®): Cellulitic injection site reaction or bacterial cellulitis?Cost-effectiveness of vaccination against herpes zoster.Herpes zoster: diagnostic, therapeutic, and preventive approaches.Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.Varicella and herpes zoster vaccine development: lessons learned.Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
P2860
Q24186050-0863961F-2820-4BFD-B0C7-8DB80118E8E8Q26796300-DB1AEF38-54AF-48B9-96DD-B9A3646B88ECQ33601337-03E6EF33-3BCB-4614-AB50-05D86A997BBDQ34291150-F5C5064B-8F3B-4494-8FA4-449D456512CFQ34376752-C017B1E8-06B7-4631-A9C6-F721AD651A8AQ35000186-FDB6C914-E5AF-4357-81F2-7C834D884290Q38120494-52C446D3-E052-4F79-B7A1-13BA9DC7C253Q38678770-7B3E2A5B-9C55-4C9B-AC10-7EA402B68C32Q38731791-2852CB2D-BE3F-433F-8D12-1B84064AF8E6Q38836789-0DC47533-03F1-451E-BC0F-4089900EA334Q42273664-A13489D2-1C27-4549-8AC2-B1695F698B71Q47607699-B0D0643F-D9AF-48C3-8FC3-231FB221B5B3Q58553251-E9414A68-503C-4182-94C5-7FFE84124ABC
P2860
Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity and safety of a ...... different two-dose schedules.
@en
Immunogenicity and safety of a live attenuated shingles
@nl
type
label
Immunogenicity and safety of a ...... different two-dose schedules.
@en
Immunogenicity and safety of a live attenuated shingles
@nl
prefLabel
Immunogenicity and safety of a ...... different two-dose schedules.
@en
Immunogenicity and safety of a live attenuated shingles
@nl
P2093
P2860
P356
P1476
Immunogenicity and safety of a ...... different two-dose schedules.
@en
P2093
Anne Fiquet
Christine Sadorge
Giancarlo Icardi
Hans C Rümke
Jordi Montero
Roland Hardt
Stéphane Thomas
Timo Vesikari
P2860
P304
P356
10.4161/HV.23412
P577
2013-01-14T00:00:00Z